ADHD Drug May Improve PTSD, TBI Symptoms

Medscape Medical News > Psychiatry
Liam Davenport
November 13, 2015

Ritalin and other Medications Improve Dyslexic and ADHD-Related Symptoms in PTSD and Traumatic Brain Injury

Researchers found that methylphenidate (Ritalin) not only improved PTSD symptoms but also depressive, postconcussive and cognitive symptoms in individuals with PTSD, TBI, or both. In contrast, galantamine (Razadyne,), commonly used to treat patients with Alzheimer’s disease, only improved episodic memory and had no effect on trauma-related symptoms.

According to Dr. Harold Levinson, this important study confirms many of his dyslexia, ADHD and related findings reported during his almost 5 decades of research. Levinson has reported that dyslexia and ADHD are two sides to a coin- both are caused by a cerebellar-vestibular (CV)—or inner-ear dysfunction. As a result, both respond very favorably to CV enhancing medications, e.g. , stimulants like Ritalin and antimotion-sickness antihistamines. Indeed, these disorders often determine anxiety and depressive symptoms.Thus the latter symptoms also respond positively to CV enhancers.

Because dyslexia is characterized by memory vs. conceptual symptoms, according to Levinson, this disorder also responds favorably to such memory-enhancing meds as Piracetam and Razadyne.

Levinson showed that a diverse group of disorders, autism, post-concussion and brain injury states, PTSD, etc., have co-existing CV dysfunctioning (dyslexia, ADHD) and so all respond favorably to the above medications.

Levinson’s insights clearly and best explain the results of Dr McAllister’s above mentioned study.

About Dr. Harold Levinson
Formerly Clinical Associate Professor of Psychiatry at New York University Medical Center, Dr. Harold Levinson is currently Director of the Levinson Medical Center for Learning Disabilities in Long Island, New York. He is a well-known neuropsychiatrist, clinical researcher and author. For more information, call 1(800)334-7323 or visit:

Image courtesy of David Castillo Dominici/

Neuropsychopharmacology. Published online October 28, 2015. Abstract

Comments are closed.